CALGB Member Site: University of California - San Francisco

描述（由申请人提供）：加州大学旧金山分校在合作小组工作方面有着悠久的历史，特别是在癌症和白血病B组。这份申请详细描述了加州大学旧金山分校海伦·迪勒家庭综合癌症中心癌症研究的范围和广度，以及加州大学旧金山分校研究人员在CALGB中的参与和领导地位。本申请分为三个部分：1 .加州大学旧金山癌症中心的主要研究兴趣/能力；组织机构团体参与和三。对小组的科学和临床贡献以及奖励期间的计划。这是UCSF新的U10申请。加州大学旧金山分校海伦·迪勒家庭综合癌症中心（UCSFHDFCCC）是一个nci指定的矩阵中心，涉及实验室，临床和人口科学领域的广泛跨学科研究人员。总的来说，UCSF-HDFCCC整合了331个成员的活动（247个项目成员，23个成员，42个准成员和19个附属成员），他们在四个主要的校园和医院工作。2。积极参与CALGB相关活动是UCSF-HDFCCC的高度优先事项。因此，建立了一个永久的CALGB基础设施，由首席研究员、内部顾问委员会、项目经理、监管分析师、研究药剂师和临床研究协调员组成。3。加州大学旧金山分校CALGB成员已经或正在担任目前活跃的7个协议的主席或联合主席，并在过去8年中担任其他6个协议的主席。此外，加州大学旧金山分校研究人员提出的8项方案已得到执行委员会的批准，并将在12个月内开放累积。除了这种科学领导，两个CALGB委员会（GU和Transplant）由加州大学旧金山分校的教师担任主席。这些在本应用程序中有详细说明。

DESCRIPTION (provided by applicant): The University of California-San Francisco has a long history of involvement in cooperative group efforts in general and in Cancer and Leukemia Group B in particular. This application describes, in detail, the scope and breadth of cancer research at the UCSF Helen Diller Family Comprehensive Cancer Center as well as the participation in and leadership positions held by UCSF investigators within CALGB. This application is divided into three sections: I. Major Research Interests/Capabilities of the University of California - San Francisco Cancer Center, II. Organization employed for institutional Group participation and III. Scientific and Clinical Contributions to the Group and Plans for the award period. This is a new U10 application for UCSF. I. The University of California-San Francisco Helen Diller Family Comprehensive Cancer Center (UCSFHDFCCC) is an NCI-designated matrix center involving a wide range of interdisciplinary research personnel in the laboratory, clinical, and population sciences. In total, the UCSF-HDFCCC integrates the activities of 331 members (247 program members, 23 members, 42 associate members, and 19 affiliate members) working at four major campus and hospital locations. II. Robust participation in CALGB related activities is a high priority in the UCSF-HDFCCC. As such, a permanent CALGB infrastructure has been created that consists of a principal investigator, internal advisory board, a program manager, regulatory analyst, investigational pharmacist and clinical research coordinators. III. UCSF CALGB members have served or are serving as chairs or co-chairs of 7 currently active protocols and have served as chairs of 6 other protocols during the past 8 years. Further, 8 protocols proposed by UCSF investigators have been approved by the Executive Committee and will be open to accrual within a 12-month time frame. In addition to this scientific leadership, two CALGB committees (GU and Transplant) are chaired by UCSF faculty. These are detailed in this application.